We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
-17.92%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$999M
AUM Growth
-$111M
Cap. Flow
+$145M
Cap. Flow %
14.51%
Top 10 Hldgs %
53.54%
Holding
68
New
18
Increased
13
Reduced
17
Closed
15

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$73.3M
2
XNCR icon
Xencor
XNCR
+$36.3M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$33.3M
4
SLDB icon
Solid Biosciences
SLDB
+$27.2M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$25.8M

Top Sells

Rank Stock Value
1
MGNX icon
MacroGenics
MGNX
+$31.8M
2
ASND icon
Ascendis Pharma A/S
ASND
+$25.6M
3
KYNB
Kyntra Bio
KYNB
+$22.2M
4
SRRK icon
Scholar Rock
SRRK
+$20.2M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$19.4M

Sector Composition

Rank Sector Weight
1 Healthcare 86.99%
2 Miscellaneous 13.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
1
argenx
ARGX
$64B
$79.3M 7.93%
+825,087
New +$73.3M
KURA icon
2
Kura Oncology
KURA
$1.13B
$74.1M 7.41%
5,276,753
+1,373,778
+35% +$18.2M
KYNB
3
Kyntra Bio
KYNB
$32.5M
$70.6M 7.06%
60,982
-19,708
-24% -$22.2M
IRWD icon
4
Ironwood Pharmaceuticals
IRWD
$682M
$55.8M 5.58%
6,425,251
+286,152
+5% +$3.28M
ASMB icon
5
Assembly Biosciences
ASMB
$694M
$54.4M 5.44%
200,404
-44,860
-18% -$13M
ONCE
6
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$44.5M 4.45%
1,136,851
+299,803
+36% +$13M
ASND icon
7
Ascendis Pharma A/S
ASND
$16.3B
$42.6M 4.26%
679,746
-407,511
-37% -$25.6M
IONS icon
8
Ionis Pharmaceuticals
IONS
$10.1B
$39.2M 3.92%
725,326
+653,000
+903% +$33.3M
KYNB
9
CALL
Kyntra Bio
KYNB
$32.5M
$38.9M 3.89%
33,632
+19,632
+140% +$22.1M
XNCR icon
10
Xencor
XNCR
$1.94B
$35.8M 3.58%
+989,018
New +$36.3M
DRNA
11
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$35.5M 3.55%
3,316,407
-485,920
-13% -$6.39M
SRRK icon
12
Scholar Rock
SRRK
$7.04B
$33.9M 3.39%
1,474,228
-893,150
-38% -$20.2M
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$27.5M 2.75%
+647,169
New +$25.8M
KZR
14
DELISTED
Kezar Life Sciences
KZR
$25M 2.5%
106,002
-22,818
-18% -$5.58M
SLDB icon
15
Solid Biosciences
SLDB
$1.05B
$23.2M 2.33%
+57,816
New +$27.2M
ASND icon
16
PUT
Ascendis Pharma A/S
ASND
$16.3B
$22.6M 2.26%
+360,000
New +$22.6M
AKCA
17
DELISTED
Akcea Therapeutics Inc
AKCA
$19.3M 1.93%
639,743
-115,377
-15% -$3.23M
GILD icon
18
CALL
Gilead Sciences
GILD
$181B
$17.8M 1.78%
285,100
-7,500
-3% -$524K
EIGR
19
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$16.2M 1.62%
53,188
+18,538
+54% +$5.99M
UBX
20
DELISTED
Unity Biotechnology
UBX
$15.7M 1.57%
96,711
– –
ASND icon
21
CALL
Ascendis Pharma A/S
ASND
$16.3B
$15.7M 1.57%
250,400
-6,600
-3% -$415K
SGMO
22
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$13.6M 1.36%
1,185,831
+842,600
+245% +$10.5M
ZLAB icon
23
Zai Lab
ZLAB
$2.93B
$13.2M 1.32%
569,377
+219,377
+63% +$4.07M
RCUS icon
24
Arcus Biosciences
RCUS
$3.72B
$13.2M 1.32%
1,223,495
-1,012,892
-45% -$11.8M
ABUS icon
25
Arbutus Biopharma
ABUS
$1B
$12.6M 1.26%
3,281,502
+2,049,702
+166% +$10.1M
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q4 2018 Portfolio in Review

As of Q4 2018, EcoR1 Capital held 68 positions worth $999M, down 10% from $1.11B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

EcoR1 Capital deployed $145M of net new capital in Q4 2018, opening 18 new positions and adding to 13 existing holdings. Its largest new stake was argenx: 825,087 shares worth $79.3M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 87% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $25.6M trimmed.

  • EcoR1 Capital's largest Q4 2018 buy was argenx: 825,087 shares worth $79.3M.
  • EcoR1 Capital added most to Ionis Pharmaceuticals in Q4 2018, an estimated $33.3M increase.
  • EcoR1 Capital's biggest Q4 2018 reduction was Ascendis Pharma A/S, cutting an estimated $25.6M.
  • EcoR1 Capital fully exited MacroGenics in Q4 2018, selling an estimated $31.8M.
  • EcoR1 Capital's ten largest holdings make up 54% of its $999M portfolio in Q4 2018.
  • EcoR1 Capital opened 18 new positions and closed 15 in Q4 2018.
  • EcoR1 Capital's portfolio value fell 10% quarter-over-quarter to $999M.

Based on EcoR1 Capital's 13F filing for Q4 2018, filed 14 Feb 2019.